Webinar: Early Response Evaluation by Single-Cell Signaling Profiling in Acute Myeloid Leukemia
CCBIO recommends this webinar January 25 where our PI Bjørn Tore Gjertsen is speaker, on the topic "Early Response Evaluation by Single-Cell Signaling Profiling in Acute Myeloid Leukemia".
Main content
Acute myeloid leukemia (AML) is a hematopoietic stem cell-derived myeloid malignancy characterized by manifold genetic aberrations and poor overall survival. See how by using a state-of-the-art 36-marker mass cytometry panel and by focusing on functional signaling analysis, Bjørn and his team were capable of shedding light on one of the most critical aspects of cancer treatment - the initial response to chemotherapy in AML patients.
Join this webinar Thursday January 25, 2024 at 16:00 to learn about:
Insights into AML response:Discover the initial signaling response to standard induction chemotherapy in a cohort of 32 AML patients.
Predicting 5-year survival: Learn about the significant predictors of patient 5-year overall survival in this cohort, specifically the reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation.
Importance of signaling pathways: See how RNA sequencing and proteomics confirm the mass cytometry data, and highlight the potential for together with mass cytometry showcases the potential of this assay to be used in the future of precision oncology.
Speaker: Bjørn Tore Gjertsen, MD, PhD, is Professor of Hematology from 2007 at the Department of Clinical Science at the University of Bergen, working as Research Chief & Consultant Hematologist at Helse Bergen Health Trust. His lab focuses on intracellular signal transduction and its regulation of the tumor suppressor protein p53. Gjertsen is PI at the Centre of Cancer Biomarkers CCBIO, where mass cytometry is developed into prognostic biomarker panels for cancer.
Register on this link.
